GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Avanir Pharmaceuticals (AVNR) [hlAlert]

Rating:
Buy AVNR
up 528.14 %

Avanir Pharmaceuticals (AVNR) rated Buy by Canaccord Adams

Posted on: Tuesday,  Apr 6, 2010  8:25 AM ET by Canaccord Adams

Canaccord Adams rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 04/06/2010, when the stock price was $2.70. Since
then, Avanir Pharmaceuticals has gained 528.15% as of 01/12/2015's recent price of $16.96.
If you would have followed this Canaccord Adams's recommendation on AVNR, you would have gained 528.14% of your investment in 1742 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Canaccord Adams provides focused, actionable, idea-driven research, helping clients make informed investment decisions. Our 55 international analysts scour the globe for emerging and small to mid cap (US$1-2 billion market capitalization) growth opportunities, identifying value and exposing risk. Our research team analyzes over 550 companies in eight sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. Our clients benefit from our thorough and sophisticated knowledge of the sectors we cover - Metals and Mining, Energy, Technology, Life Sciences, Real Estate, Consumer, Sustainability and Industrial Growth. We combine independent, actionable ideas, unique global perspective and unparalleled industry expertise. We believe it's evident in our research, and the foundation of our business.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/6/2010 8:25 AM Buy
None
2.70
as of 12/31/2010
1 Week down  -2.58 %
1 Month down  -2.58 %
3 Months up  29.78 %
1 YTD up  53.33 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/6/2010 8:25 AM Buy
None
2.70

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy